Home
/

Best Supplements for ADHD: Focus and Attention Support

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

The most evidence-backed supplements for ADHD target specific nutrient-dopamine pathways — zinc inhibits dopamine reuptake, iron is required for dopamine synthesis, and magnesium blocks NMDA receptors. Zinc supplementation is associated with meaningful improvements in ADHD symptom scores in documented deficiency; test zinc, ferritin, and magnesium first, as benefit is minimal when baseline is normal.

Read more →
Table of contents

What Happens in the ADHD Brain That Supplements Might Address

ADHD involves dysregulation of dopamine and norepinephrine, the neurotransmitters that govern attention, impulse control, and executive function. Brain imaging shows reduced activation in prefrontal and anterior cingulate circuits involved in inhibition and attention, and altered dopamine transporter density. A 2012 meta-analysis found transporter density varies with medication history: lower in those who have never been medicated, higher in those previously treated.

Several micronutrients serve as cofactors in neurotransmitter synthesis or directly modulate receptor function. Deficiencies in zinc, iron, magnesium, or omega-3s can worsen attention, focus, and behavioral regulation in individuals with ADHD by disrupting these pathways at a biochemical level. That's why baseline testing matters before you start any supplementation.

How specific nutrients connect to dopamine

Zinc binds directly to dopamine transporters and slows reuptake through non-competitive inhibition, a different mechanism than stimulant medications. Iron is required for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Without adequate iron, dopamine production stalls regardless of other interventions.

DHA makes up a substantial portion of neuronal cell membranes, enriching to roughly 30–40% of fatty acids in key phospholipid fractions such as phosphatidylethanolamine and phosphatidylserine in cortical gray matter (approximately 10–14% of total phospholipid fatty acids overall), and influences receptor sensitivity and inflammatory signaling. Magnesium acts as a voltage-dependent blocker of NMDA receptors, controlling neuronal firing rates through this channel-blocking mechanism. Low magnesium reduces this inhibitory effect, which may present as heightened excitability, irritability, and disrupted sleep.

These nutrients don't generate new neurotransmitters. They support the machinery that produces, transports, and responds to dopamine. Correcting a deficiency can restore normal function; supplementing when you're already replete typically adds nothing.

How These Supplements Affect Dopamine, Attention, and Behavior

Omega-3 fatty acids and brain membrane function

EPA and DHA integrate into neuronal membranes and influence how receptors respond to neurotransmitters. Earlier meta-analyses suggested EPA may be more relevant to supporting attention-related outcomes than DHA, it modulates inflammatory pathways and may improve dopamine signaling by reducing neuroinflammation, though the most recent meta-analyses have not confirmed a consistent EPA dose-response effect. A 2018 meta-analysis and biological review found children with ADHD consistently show lower DHA, EPA, and total omega-3 levels than neurotypical peers across case-control studies.

Trial results are mixed. The 2023 Cochrane review found no effect on parent-rated ADHD symptoms across 37 studies. An earlier 2011 meta-analysis of 10 RCTs reported small but significant improvements, with EPA dose within supplements associated with efficacy. Any effect appears modest and context-dependent.

Zinc and dopamine transporter regulation

Zinc binds to dopamine transporters and reduces the reuptake rate through non-competitive inhibition. Children with ADHD often have lower serum zinc than neurotypical peers. A 2022 meta-analysis found zinc supplementation significantly improved total ADHD symptom scores in six randomized trials, with effects most pronounced in those with documented low baseline levels.

Iron and dopamine synthesis

Iron is essential for tyrosine hydroxylase, which converts tyrosine into L-DOPA, dopamine's direct precursor. A systematic review found that ferritin, the storage form of iron, runs consistently low in children with ADHD. A small RCT in iron-deficient children found supplementation may reduce symptom severity; normal ferritin levels produce no additional benefit.

Magnesium and neuronal excitability

Magnesium acts as a voltage-dependent blocker of NMDA receptors, opposing calcium entry through these channels, and modulates neuronal firing rates through this mechanism. A meta-analysis confirmed that those with ADHD have significantly lower serum magnesium levels than controls. Low magnesium can manifest as heightened excitability, irritability, and poor sleep quality.

What the Clinical Evidence Actually Shows About ADHD Supplements

Omega-3 fatty acids: mixed evidence, small effect at best

A 2023 Cochrane review of 37 trials (2,374+ participants total) found high-certainty evidence that PUFA supplementation has no effect on parent-rated ADHD symptoms (based on 16 trials with 1,166 participants rated for this outcome). A separate 2023 meta-analysis of 22 RCTs showed a non-significant overall effect (SMD: −0.16), though supplementation lasting at least four months showed a modest benefit (SMD: −0.35).

Earlier meta-analyses reported larger effect sizes, the Bloch & Qawasmi 2011 meta-analysis of 10 RCTs found a small but significant benefit, and the Chang et al. 2018 meta-analysis reported an effect size of g=0.38, but the most comprehensive recent reviews are less favorable. Any benefit appears limited to those with low baseline omega-3 levels who supplement for at least four months. Treat omega-3s as an adjunct to other strategies, not a standalone approach.

Zinc: promising in deficient populations

A 2022 dose-response meta-analysis of six RCTs with 489 children found zinc supplementation significantly improved total ADHD symptom scores (SMD: −0.62), though evidence certainty ranged from moderate to very low and confidence intervals were wide (95% CI: −1.24 to −0.002). The benefit concentrates in those with documented deficiency, supplementing when baseline zinc is normal shows minimal to no effect.

Iron: effective when ferritin is low

Research suggests iron supplementation may help support attention when ferritin falls below 30 ng/mL. A small RCT of 23 children found 80 mg/day of ferrous sulfate over 12 weeks significantly reduced ADHD Rating Scale scores versus placebo. A 2024 systematic review rated overall evidence quality as very low, reinforcing why testing before supplementing is essential.

Iron supplementation when ferritin is already normal is unlikely to support attention and focus and may cause GI side effects or oxidative damage. Test first.

Magnesium: context-dependent results

The magnesium evidence is thinner than for zinc or iron. An open-label prospective study (40 children, no placebo arm) found that magnesium plus vitamin B6 significantly reduced hyperactivity and improved attention in children with ADHD and low baseline levels; symptoms returned when supplementation stopped. A double-blind RCT of 66 children found vitamin D and magnesium co-supplementation reduced conduct problems and social difficulties on the Conners' Parent Rating Scale over 8 weeks. Both studies have significant methodological limitations and neither isolates magnesium as the sole active component.

Dosing, Forms, and Timing That Matter

The doses below are drawn from clinical research and are provided for informational purposes. Consult a healthcare provider before starting any supplement regimen, particularly if you are pregnant, taking medications, or considering supplementation for a child.

Omega-3 fatty acids

Effective doses in ADHD trials range from 500 to 1,000 mg of EPA daily, often combined with 200–500 mg of DHA. Most trials have used EPA-dominant formulas, though whether a higher EPA-to-DHA ratio is itself the driver of any benefit remains uncertain. Omega-3s are fat-soluble, take them with meals for better absorption. Triglyceride and phospholipid forms absorb more efficiently than ethyl ester forms, and consistency over weeks matters more than timing.

Look for high-potency omega-3 formulas that specify EPA content on the label, not just total fish oil weight.

Zinc

Studied doses range from 15 to 30 mg elemental zinc daily, typically as zinc bisglycinate or zinc sulfate. Zinc bisglycinate is better tolerated and less likely to cause nausea. Zinc competes with copper for absorption, prolonged use above 30 mg/day can deplete copper. Take zinc with food to minimize GI side effects and retest levels after 8–12 weeks.

Iron

ADHD trials typically use 40–80 mg elemental iron daily, often as ferrous sulfate. Iron absorbs best on an empty stomach, but nausea is common, a small amount of food is a reasonable trade-off. Vitamin C enhances iron absorption; calcium, tea, and coffee inhibit it. Test ferritin before starting and retest to avoid iron overload, which carries cardiovascular and oxidative risks.

Magnesium

Doses in ADHD trials range from 200 to 400 mg elemental magnesium daily, typically as magnesium bisglycinate or magnesium citrate. Bisglycinate absorbs better and causes fewer GI effects than magnesium oxide. Take magnesium in the evening, it promotes relaxation and may improve sleep. Splitting the dose reduces the risk of loose stools.

Why Responses Vary and Who Should Use Caution

Supplement responses in ADHD depend heavily on baseline nutrient status. Low zinc, iron, or magnesium creates conditions where supplementation may be associated with measurable changes. Normal levels do not. Genetic differences in nutrient metabolism also play a role, variants in the FADS1/FADS2 fatty acid desaturase genes affect how efficiently the body converts ALA to EPA and DHA, and dopamine transporter gene variants may influence zinc-related responses, though the clinical implications of these polymorphisms for supplementation decisions are not yet established.

Age matters too. Most ADHD supplement studies focus on children, and it's unclear whether the same effects apply to adults. Children have higher nutrient demands due to growth, and deficiencies may be more prevalent. Adults with ADHD may benefit from omega-3s or magnesium for general brain health, but the evidence for adult symptom-specific improvement is weaker.

Several medication interactions are worth knowing:

Who should avoid or use caution with specific supplements:

  • Hemochromatosis or elevated ferritin: avoid iron supplementation entirely.
  • Kidney disease: avoid magnesium without medical supervision, impaired clearance can cause hypermagnesemia.
  • Zinc above 100 mg/day can suppress immune function, but the 15–30 mg doses used in ADHD trials fall well below this threshold.
  • A systematic review found no evidence that fish oil increases perioperative bleeding risk.

Turning Supplement Research Into a Strategy That Works for You

The most actionable first step is testing baseline nutrient levels before supplementing. Ferritin and serum zinc give you objective data on where you're deficient versus replete. Supplementing without this data wastes money and risks unintended nutrient imbalances, particularly with iron and zinc, where excess causes real harm.

Track symptoms systematically over time. ADHD symptoms fluctuate naturally, so subjective impressions can mislead. Use a validated rating scale before and after an 8–12 week trial. If symptoms improve, the supplement may be contributing. If nothing changes, discontinue, continuing without evidence of benefit is unnecessary.

Biomarkers to retest after supplementing:

  • Ferritin, reflects iron stores; target 50–150 ng/mL for most adults
  • Serum zinc, confirms whether zinc status is normalizing
  • RBC magnesium, more accurate than serum magnesium for intracellular status
  • Omega-3 index, tracks EPA and DHA levels in red blood cells

Test Your Levels, Then Decide

Taking supplements for ADHD without testing first means guessing which deficiencies you have, if any. Superpower's comprehensive baseline panel includes ferritin and iron as standard markers. Add zinc and RBC magnesium to get a full picture of the nutrients most relevant to ADHD. Test before you start, retest after 8–12 weeks, and adjust your stack based on what the numbers actually show. That's how supplementation becomes a strategy instead of a gamble.

FAQs

Zinc and iron have the strongest evidence for supporting attention and focus, but only in those with documented deficiencies. Omega-3 fatty acids have been widely studied, though the most comprehensive reviews show limited effect on core ADHD symptoms. Magnesium may help support healthy activity levels and sleep quality in those with low baseline levels. In every case, benefit depends on starting nutrient status, and testing before supplementing is the recommended approach.

No. The most comprehensive evidence suggests omega-3 supplementation produces limited improvement in ADHD symptoms, with effect sizes far smaller than stimulant medications. Omega-3s work best as an adjunct to behavioral strategies or medication, not as a replacement. If you're considering stopping medication, discuss it with your prescriber rather than substituting supplements unilaterally.

Omega-3s typically require 8–12 weeks to show effects, since saturating neuronal membranes takes time. Zinc and magnesium may produce changes within 4–8 weeks. Iron supplementation may help support focus and attention within 8–12 weeks when ferritin is low. If there's no improvement after 12 weeks, the supplement is unlikely to be contributing to symptom changes, and continuing it is hard to justify.

Yes. Testing ferritin, serum zinc, and RBC magnesium before supplementing identifies true deficiencies and prevents unnecessary supplementation. Supplementing nutrients you're not deficient in rarely helps and may cause side effects or nutrient imbalances, especially with iron, where excess is harmful. Testing also gives you a baseline to confirm whether supplementation is actually correcting a deficiency over time.

Omega-3s, zinc, iron, and magnesium are generally safe for children when dosed appropriately and monitored by a healthcare provider. Iron supplementation should only be used when ferritin is documented to be low, excess iron in children can be harmful. Zinc above 30 mg/day may deplete copper, and doses above 100 mg/day can suppress immune function, though ADHD trial doses fall well below this level. Always consult a pediatrician before starting supplements in children.

Research suggests magnesium may support relaxation and sleep quality in children with ADHD, particularly those with low baseline levels. It modulates NMDA receptors and reduces neuronal excitability, which can ease bedtime restlessness. Magnesium bisglycinate taken in the evening is the best-tolerated form for sleep support and causes the fewest GI side effects compared to other forms.

References

  1. Hart, H., Radua, J., Nakao, T., Mataix-Cols, D., & Rubia, K. (2013). Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA psychiatry, 70(2), 185-98. https://doi.org/10.1001/jamapsychiatry.2013.277
  2. Fusar-Poli, P., Rubia, K., Rossi, G., Sartori, G., & Balottin, U. (2012). Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. The American journal of psychiatry, 169(3), 264-72. https://doi.org/10.1176/appi.ajp.2011.11060940
  3. Norregaard, L., Frederiksen, D., Nielsen, E. O., & Gether, U. (1998). Delineation of an endogenous zinc-binding site in the human dopamine transporter. The EMBO journal, 17(15), 4266-73. https://doi.org/10.1093/emboj/17.15.4266
  4. Daubner, S. C., Le, T., & Wang, S. (2011). Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of biochemistry and biophysics, 508(1), 1-12. https://doi.org/10.1016/j.abb.2010.12.017
  5. Glomset, J. A. (2006). Role of docosahexaenoic acid in neuronal plasma membranes. Science's STKE : signal transduction knowledge environment, 2006(321), pe6. https://doi.org/10.1126/stke.3212006pe6
  6. Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984). Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature, 309(5965), 261-3. https://doi.org/10.1038/309261a0
  7. Liu, T. H., Wu, J. Y., Huang, P. Y., Lai, C. C., Chang, J. P., Lin, C. H., & Su, K. P. (2023). Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. The Journal of clinical psychiatry, 84(5). https://doi.org/10.4088/JCP.22r14772
  8. Chang, J. P., Su, K. P., Mondelli, V., & Pariante, C. M. (2018). Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(3), 534-545. https://doi.org/10.1038/npp.2017.160
  9. Gillies, D., Leach, M. J., & Perez Algorta, G. (2023). Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. The Cochrane database of systematic reviews, 4(4), CD007986. https://doi.org/10.1002/14651858.CD007986.pub3
  10. Bloch, M. H., & Qawasmi, A. (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 50(10), 991-1000. https://doi.org/10.1016/j.jaac.2011.06.008
  11. Lepping, P., & Huber, M. (2010). Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment. CNS drugs, 24(9), 721-8. https://doi.org/10.2165/11537610-000000000-00000
  12. Talebi, S., Miraghajani, M., Ghavami, A., & Mohammadi, H. (2022). The effect of zinc supplementation in children with attention deficit hyperactivity disorder: A systematic review and dose-response meta‑analysis of randomized clinical trials. Critical reviews in food science and nutrition, 62(32), 9093-9102. https://doi.org/10.1080/10408398.2021.1940833
  13. Wang, Y., Huang, L., Zhang, L., Qu, Y., & Mu, D. (2017). Iron Status in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. PloS one, 12(1), e0169145. https://doi.org/10.1371/journal.pone.0169145
  14. Konofal, E., Lecendreux, M., Deron, J., Marchand, M., Cortese, S., Zaïm, M., Mouren, M. C., & Arnulf, I. (2008). Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatric neurology, 38(1), 20-6. https://doi.org/10.1016/j.pediatrneurol.2007.08.014
  15. Effatpanah, M., Rezaei, M., Effatpanah, H., Effatpanah, Z., Varkaneh, H. K., Mousavi, S. M., Fatahi, S., Rinaldi, G., & Hashemi, R. (2019). Magnesium status and attention deficit hyperactivity disorder (ADHD): A meta-analysis. Psychiatry research, 274, 228-234. https://doi.org/10.1016/j.psychres.2019.02.043
  16. Elliott, S. D., Vickers, M. L., McKeon, G., Eriksson, L., Malacova, E., & Scott, J. G. (2024). Iron Supplementation in Management of Neurodevelopmental Disorders: Systematic Review, Meta-Analysis, and Qualitative Synthesis. The Journal of neuropsychiatry and clinical neurosciences, 36(3), 178-186. https://doi.org/10.1176/appi.neuropsych.20230081
  17. Mousain-Bosc, M., Roche, M., Polge, A., Pradal-Prat, D., Rapin, J., & Bali, J. P. (2006). Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnesium research, 19(1), 46-52. https://pubmed.ncbi.nlm.nih.gov/16846100/
  18. Hemamy, M., Heidari-Beni, M., Askari, G., Karahmadi, M., & Maracy, M. (2020). Effect of Vitamin D and Magnesium Supplementation on Behavior Problems in Children with Attention-Deficit Hyperactivity Disorder. International journal of preventive medicine, 11, 4. https://doi.org/10.4103/ijpvm.IJPVM_546_17
  19. Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010). Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, leukotrienes, and essential fatty acids, 83(3), 137-41. https://doi.org/10.1016/j.plefa.2010.06.007
  20. Brookes, K. J., Chen, W., Xu, X., Taylor, E., & Asherson, P. (2006). Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biological psychiatry, 60(10), 1053-61. https://doi.org/10.1016/j.biopsych.2006.04.025
  21. Eljaaly, K., Helal, A., Almandeel, T., Algarni, R., & Alshehri, S. (2021). Multivalent cations interactions with fluoroquinolones or tetracyclines: A cross-sectional study. Saudi journal of biological sciences, 28(12), 6929-6932. https://doi.org/10.1016/j.sjbs.2021.07.065
  22. Wiesner, A., Gajewska, D., & Paśko, P. (2021). Levothyroxine Interactions with Food and Dietary Supplements-A Systematic Review. Pharmaceuticals (Basel, Switzerland), 14(3). https://doi.org/10.3390/ph14030206
  23. Javaid, M., Kadhim, K., Bawamia, B., Cartlidge, T., Farag, M., & Alkhalil, M. (2024). Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of the American Heart Association, 13(10), e032390. https://doi.org/10.1161/JAHA.123.032390
  24. Chandra, R. K. (1984). Excessive intake of zinc impairs immune responses. JAMA, 252(11), 1443-6. https://pubmed.ncbi.nlm.nih.gov/6471270/
  25. Begtrup, K. M., Krag, A. E., & Hvas, A. M. (2017). No impact of fish oil supplements on bleeding risk: a systematic review. Danish medical journal, 64(5). https://pubmed.ncbi.nlm.nih.gov/28552094/

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey